AR090293A1 - Inhibidores de quinasa a base de arileter - Google Patents
Inhibidores de quinasa a base de arileterInfo
- Publication number
- AR090293A1 AR090293A1 ARP130100766A ARP130100766A AR090293A1 AR 090293 A1 AR090293 A1 AR 090293A1 AR P130100766 A ARP130100766 A AR P130100766A AR P130100766 A ARP130100766 A AR P130100766A AR 090293 A1 AR090293 A1 AR 090293A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- halo
- alkoxy
- hydrogen
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 9
- 125000001475 halogen functional group Chemical group 0.000 abstract 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 7
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- -1 C1−3-amino alkyl Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 abstract 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000003566 oxetanyl group Chemical group 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos que pueden inhibir la AAK1 (quinasa asociada con el adaptador 1), composiciones que comprenden tales compuestos y métodos para inhibir la AAK1. Útil para tratar esquizofrenia, Parkinson, dolor neuropático, trastorno bipolar y Alzheimer. Reivindicación 1: Un compuesto caracterizado por la fórmula (1) o una de sus sales farmacéuticamente aceptables, en donde: R¹ y R² están seleccionados, de modo independiente, de hidrógeno, cicloalquilo C₃₋₆ y alquilo C₁₋₃, en donde el alquilo C₁₋₃ está opcionalmente sustituido con uno, dos o tres grupos seleccionados, de modo independiente, de alcoxi C₁₋₃, alquil C₁₋₃-amino, amino, ciano, dialquil C₁₋₃-amino, halo e hidroxi; o R¹ y R² juntos son oxo; o R¹ y R², junto con el átomo de carbono al que están unidos, forman un anillo oxetano; R³ es alquil C₁₋₃-Y o alquilo C₂₋₈, en donde el alquilo C₂₋₈ está opcionalmente sustituido con uno, dos, tres o cuatro grupos seleccionados, de modo independiente, de alcoxi C₁₋₃, alquil C₁₋₃-amino, alcoxi C₁₋₃-alquil C₂₋₃-amino, amino, arilo, halo, haloalquil C₁₋₃-amino, haloalquil C₁₋₃-carbonilamino, hidroxi, -NRˣRʸ y cicloalquilo C₃₋₈, en donde el cicloalquilo está también opcionalmente sustituido con uno, dos o tres grupos seleccionados, de modo independiente, de alcoxi C₁₋₃, alquilo C₁₋₃, alquil C₁₋₃-amino, alcoxi C₁₋₃-alquil C₂₋₃-amino, amino, arilo, arilalquilo C₁₋₃, halo, haloalquilo C₁₋₃, haloalquil C₁₋₃-amino e hidroxi; R⁴ está seleccionado de hidrógeno, alcoxi C₁₋₃, alcoxi C₁₋₃-carbonilamino, alquilo C₁₋₃, alquil C₁₋₃-amino, alquil C₁₋₃-carbonilamino, amino, arilamino, arilcarbonilamino, cicloalquil C₃₋₆-amino, cicloalquil C₃₋₆-carbonilamino, cicloalquil C₃₋₆-oxi, halo, haloalcoxi C₁₋₃, haloalquil C₂₋₃amino, haloalquil C₂₋₃carbonilamino e hidroxi; R⁵ está seleccionado de hidrógeno, alquilo C₁₋₃, ciano, cicloalquilo C₃ y halo; R⁶ está seleccionado de hidrógeno, alquilo C₁₋₃, alquil C₁₋₃-carbonilamino, amino; R⁷ está seleccionado de hidrógeno, alcoxi C₁₋₃, alquilo C₁₋₃, ciano, -CH₂OH, -CH₂OCH₃, CH(CH₃)OH, C(CH₃)₂OH, halo y haloalquilo C₁₋₃; R⁸ está seleccionado de hidrógeno, alcoxi C₁₋₃, ciano y halo; Rˣ y Rʸ, junto con el átomo de nitrógeno al que están unidos, forman un anillo de tres a seis miembros; e Y está seleccionado del grupo de fórmulas (2); en donde R⁹ está seleccionado de hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ y alquil C₁₋₆-carbonilo; n es 0, 1, 2 ó 3; cada R¹⁰ está seleccionado, de modo independiente, de hidrógeno, alquilo C₁₋₆, arilo, arilalquilo C₁₋₃, cicloalquilo C₃₋₆, halo y haloalquilo C₁₋₃; y cada R¹¹ está seleccionado, de modo independiente, de hidrógeno, alcoxi C₁₋₃ e hidroxi.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608737P | 2012-03-09 | 2012-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090293A1 true AR090293A1 (es) | 2014-11-05 |
Family
ID=47892007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100766A AR090293A1 (es) | 2012-03-09 | 2013-03-11 | Inhibidores de quinasa a base de arileter |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8703953B2 (es) |
| EP (1) | EP2822952B1 (es) |
| JP (1) | JP2015510881A (es) |
| CN (1) | CN104144932A (es) |
| AR (1) | AR090293A1 (es) |
| CA (1) | CA2866671A1 (es) |
| EA (1) | EA201491647A1 (es) |
| MX (1) | MX2014010684A (es) |
| TW (1) | TW201341387A (es) |
| UY (1) | UY34666A (es) |
| WO (1) | WO2013134036A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8901305B2 (en) | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| WO2014130258A1 (en) | 2013-02-22 | 2014-08-28 | Bristol-Myers Squibb Company | 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1) |
| ES2634628T3 (es) | 2013-07-02 | 2017-09-28 | Bristol-Myers Squibb Company | Derivados tricíclicos de pirido-carboxamida como inhibidores ROCK |
| US9914740B2 (en) | 2013-07-02 | 2018-03-13 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
| WO2015006100A1 (en) | 2013-07-08 | 2015-01-15 | Bristol-Myers Squibb Company | Aryl amide kinase inhibitors |
| MX2016002924A (es) * | 2013-09-11 | 2016-06-06 | Squibb Bristol Myers Co | Inhibidores de cinasa a base de eter arilico. |
| JP6473146B2 (ja) | 2013-10-11 | 2019-02-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピロロトリアジンキナーゼ阻害剤 |
| EP3099300B1 (en) * | 2014-01-29 | 2018-09-05 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| CN106132951B (zh) * | 2014-01-31 | 2019-02-12 | 百时美施贵宝公司 | 基于喹啉的激酶抑制剂 |
| DK3126351T3 (en) * | 2014-04-02 | 2019-01-14 | Bristol Myers Squibb Co | BIARYLKINASE INHIBITORS |
| US10174044B2 (en) | 2015-04-10 | 2019-01-08 | Bristol-Myers Squibb Company | Fused pyridines as kinase inhibitors |
| BR112017019207A2 (pt) * | 2015-05-22 | 2018-04-24 | Dow Agrosciences Llc | recuperação e/ou reutilização de catalisador de paládio após acoplamento de suzuki |
| KR102704295B1 (ko) * | 2015-10-01 | 2024-09-05 | 브리스톨-마이어스 스큅 컴퍼니 | 비아릴 키나제 억제제 |
| WO2017059080A1 (en) * | 2015-10-01 | 2017-04-06 | Bristol-Myers Squibb Company | Biaryl kinase inhibitors |
| WO2018109050A1 (en) | 2016-12-15 | 2018-06-21 | F. Hoffmann-La Roche Ag | Process for preparing btk inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU673569B2 (en) | 1992-12-02 | 1996-11-14 | Pfizer Inc. | Catechol diethers as selective PDE-IV inhibitors |
| US5709861A (en) | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
| US20070060606A1 (en) * | 1999-10-07 | 2007-03-15 | Robertson Harold A | Compounds and methods for modulating phosphodiesterase 10A |
| ES2301793T3 (es) | 2002-04-05 | 2008-07-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Cianamidas utiles como inhibidores reversibles de cisteina proteasas. |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| US7601868B2 (en) | 2003-02-12 | 2009-10-13 | Takeda Pharmaceutical Company Limited | Amine derivative |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| CA2570694A1 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| CN100494167C (zh) | 2005-08-02 | 2009-06-03 | 天津大学 | 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用 |
| JP2007217408A (ja) | 2006-01-19 | 2007-08-30 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| SI2007756T1 (sl) | 2006-04-07 | 2015-11-30 | Vertex Pharmaceuticals Incorporated | Modulatorji prenašalcev z atp-vezavno kaseto |
| US20080039535A1 (en) | 2006-08-14 | 2008-02-14 | Wyeth | Methods of identifying agents for treating neurological disorders |
| CA2688299A1 (en) * | 2007-05-29 | 2008-12-18 | President And Fellows Of Harvard College | Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof |
| DE102007025717A1 (de) * | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
| US8497271B2 (en) | 2009-10-07 | 2013-07-30 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8426414B2 (en) | 2009-10-09 | 2013-04-23 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
-
2013
- 2013-02-26 US US13/777,144 patent/US8703953B2/en active Active
- 2013-02-28 CN CN201380012323.6A patent/CN104144932A/zh active Pending
- 2013-02-28 JP JP2014560950A patent/JP2015510881A/ja not_active Withdrawn
- 2013-02-28 MX MX2014010684A patent/MX2014010684A/es unknown
- 2013-02-28 WO PCT/US2013/028230 patent/WO2013134036A1/en not_active Ceased
- 2013-02-28 CA CA2866671A patent/CA2866671A1/en not_active Abandoned
- 2013-02-28 EA EA201491647A patent/EA201491647A1/ru unknown
- 2013-02-28 EP EP13710203.4A patent/EP2822952B1/en active Active
- 2013-03-08 UY UY0001034666A patent/UY34666A/es unknown
- 2013-03-08 TW TW102108352A patent/TW201341387A/zh unknown
- 2013-03-11 AR ARP130100766A patent/AR090293A1/es unknown
-
2014
- 2014-02-24 US US14/188,141 patent/US8969564B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8969564B2 (en) | 2015-03-03 |
| TW201341387A (zh) | 2013-10-16 |
| JP2015510881A (ja) | 2015-04-13 |
| EP2822952A1 (en) | 2015-01-14 |
| CN104144932A (zh) | 2014-11-12 |
| WO2013134036A1 (en) | 2013-09-12 |
| EA201491647A1 (ru) | 2014-12-30 |
| US20130237555A1 (en) | 2013-09-12 |
| EP2822952B1 (en) | 2016-04-06 |
| UY34666A (es) | 2013-09-30 |
| US8703953B2 (en) | 2014-04-22 |
| MX2014010684A (es) | 2014-10-17 |
| US20140179725A1 (en) | 2014-06-26 |
| CA2866671A1 (en) | 2013-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090293A1 (es) | Inhibidores de quinasa a base de arileter | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR129635A2 (es) | Moduladores de tetrahidropiridopirazina de gpr6 | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR105103A1 (es) | Derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR105101A1 (es) | Derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| PE20200008A1 (es) | Isoquinolinas como inhibidores de hpk1 | |
| AR090230A1 (es) | Derivados macrociclicos para el tratamiento de enfermedades | |
| CR20220157A (es) | Procedimiento para preparar (4s)–4–(4–ciano–2–metoxi–fenil)–5–etoxi–2,8–dimetil–1,4–dihidro–1,6–naftiridin–3–carboxilato de 2–cianoetilo mediante separación de racematos utilizando ésteres diastereoméricos de ácido tartárico | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| AR062011A1 (es) | Derivados de diazol y sus composiciones como inhibidores de itpkb | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR093579A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
| AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
| AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR085748A1 (es) | Piridinonas biciclicas | |
| AR110498A1 (es) | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR087771A1 (es) | Moduladores de la pde10 | |
| AR093758A1 (es) | Inhibidores de aril lactama quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |